Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Determination method of urine metabolic marker for early diagnosis of diabetic nephropathy.

A technology for diabetic nephropathy and metabolic markers, which is applied in the direction of measuring devices, instruments, scientific instruments, etc., can solve the problems of undetected diabetic nephropathy and false positives, and achieve the effects of preventing irreversible changes, strong specificity, and convenient operation

Inactive Publication Date: 2013-01-30
NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A +1
View PDF0 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] 2. false positive When 20mg / L is used as the cut-off value, many healthy people with negative urinary albumin will also have false positive results
At present, there is no report on the use of metabolomics detection methods to detect molecules in urine to predict the occurrence of early diabetic nephropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Determination method of urine metabolic marker for early diagnosis of diabetic nephropathy.
  • Determination method of urine metabolic marker for early diagnosis of diabetic nephropathy.
  • Determination method of urine metabolic marker for early diagnosis of diabetic nephropathy.

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The present invention is explained in detail by the following examples, but it does not mean that the present invention is limited thereto.

[0017] Determination method of urine metabolic markers for early diagnosis of diabetic nephropathy

[0018] 1. Experimental Protocol and Sample Collection

[0019] 30 healthy people and 90 diabetic nephropathy patients (divided into three stages of early, middle and late stages) were respectively measured for their 24-hour urine microalbumin excretion, glycosylated hemoglobin value, blood cholesterol, triglyceride, high-density lipoprotein, low Density lipoprotein and other biochemical indicators (Table 1), according to clinical standards, the patients were divided into three stages of diabetic nephropathy, early stage of diabetic nephropathy, middle stage of diabetic nephropathy, and late stage of diabetic nephropathy. 1ml of blood was collected from the control group and patients after fasting for 12 hours, and their 12-hour ur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a determination method of a urine metabolic marker for early diagnosis of diabetic nephropathy. The method mainly utilizes analysis technique and method such as gas mass spectrometry and mass liquid spectrometry for quantitative determination of endogenous small molecule compounds in urine of patients with diabetes and diabetic nephropathy; and relative concentration difference between endogenous small molecule compounds in a pathological group and a normal group is calculated and compared, so as to be applied to clinical early diagnosis of diabetic nephropathy. Compared with other existing clinical diagnosis indexes, the method has advantages of wide adaptation range, sensitivity, simple sampling and operation, and no harm on the body. The method is more suitable for screening of diabetic nephropathy in early stage with some uncertain physiological and biochemical indexes, so as to avoid missing of the best treatment time due to delayed diagnosis.

Description

technical field [0001] The invention relates to a method for measuring clinical diagnostic markers of diabetic nephropathy, in particular to detecting endogenous small molecules in human urine samples by using gas chromatography mass spectrometry and liquid chromatography mass spectrometry, and using relative quantitative or absolute quantitative methods to measure urine of patients with diabetes and diabetic nephropathy. The endogenous small molecules in the urine are compared with the range of small molecules in normal human urine as the basis for judgment. Background technique [0002] For a long time, the diagnostic indicators and methods of clinical diabetic nephropathy mainly include the determination of urinary albumin and serum creatinine. These indicators do not change significantly in the early stage and are prone to false positive results. Although living kidney tissue is more accurate, it is harmful to the human body and cannot be used as a routine screening meth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/88
Inventor 刘志红王广基阿基业李梦婕王旭方刘林生秦卫松曹蓓葛永纯石建
Owner NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com